James Bailey, MD
Family Medicine · Stow, OHNPI 1669458782
Payments from drug & device makers
Across 319 payments — averaging $12.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$649
- AbbVie$524
- Novo Nordisk$369
- Takeda Pharmaceuticals U.S.A., Inc.$287
- Pfizer$278
- Lilly USA, LLC$255
- plus $2K from 36 others
What the payments were for
- Food & beverage$4,113100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $649 |
| AbbVie(2 entities) | 60 | $524 |
| Novo Nordisk | 44 | $369 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $287 |
| Pfizer | 28 | $278 |
| Lilly USA, LLC | 17 | $255 |
| Novartis | 14 | $206 |
| Astellas Pharma US Inc | 12 | $176 |
| Boehringer Ingelheim | 14 | $171 |
| Gilead | 5 | $91 |
| Abbott | 5 | $90 |
| Amgen | 5 | $85 |
| Phathom Pharmaceuticals, Inc. | 6 | $80 |
| Bayer | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 4 | $58 |
| Merck | 4 | $58 |
| Corcept Therapeutics | 3 | $57 |
| GSK | 4 | $53 |
| Genentech USA, Inc. | 3 | $50 |
| Amarin Pharma, Inc. | 3 | $45 |
| Johnson & Johnson | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $33 |
| Corium, LLC | 2 | $30 |
| Medtronic(2 entities) | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Vertical Pharmaceuticals, LLC | 2 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Pinnacle Biologics, Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Bavarian Nordic A/s | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| TMS Neurohealth Centers Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$4,121 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $154,073 |
| JardianceEmpagliflozin | 148 | $131,950 |
| OzempicSemaglutide | 94 | $103,936 |
| JanuviaSitagliptin Phosphate | 56 | $78,703 |
| TrulicityDulaglutide | 22 | $39,248 |
| XareltoRivaroxaban | 29 | $35,785 |
| FarxigaDapagliflozin Propanediol | 44 | $35,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $33,073 |
| EntrestoSacubitril/Valsartan | 17 | $27,361 |
| RybelsusSemaglutide | 20 | $25,504 |
| MounjaroTirzepatide | 15 | $19,249 |
| MyrbetriqMirabegron | 21 | $16,279 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $14,875 |
| LinzessLinaclotide | 12 | $12,170 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $11,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $278 | $154,073135 claims |
| Boehringer IngelheimJardiance | $171 | $131,950148 claims |
| Novo NordiskOzempic, Rybelsus | $369 | $129,440114 claims |
| MerckJanuvia | $58 | $78,70356 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $255 | $60,61849 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Pulmicort Flexhaler | $649 | $47,63067 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $53 | $47,18672 claims |
| Johnson & JohnsonXarelto | $44 | $35,78529 claims |
| NovartisEntresto | $206 | $27,36117 claims |
| Astellas Pharma US IncMyrbetriq | $176 | $16,27921 claims |
| AbbVieLinzess | $524 | $12,17012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Stow
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.